Jump to main content
Jump to site search


Improving solubility and storage stability of rifaximin via solid-state solvation with Transcutol®

Author affiliations

Abstract

Crystallization of rifaximin from 2-(2-ethoxyethoxy)ethanol (Transcutol®, DEGME or DEGEE), an inactive ingredient approved by the FDA and a solvent commonly used in the pharmaceutical and cosmetic fields, affords a crystalline form of the API with better solubility properties with respect to the known crystalline hydrates, which are characterized by a very low solubility in water and in buffered solutions. The new form, named rifaximin τ, is an anhydrous solvate, fully characterized by single crystal X-ray diffraction, differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). Solubility properties were also investigated and compared with known forms of rifaximin. Rifaximin τ combines a high dissolution rate, comparable to that of amorphous rifaximin, with a high storage stability, as in its solid form it is not affected by exposure to humidity.

Graphical abstract: Improving solubility and storage stability of rifaximin via solid-state solvation with Transcutol®

Back to tab navigation

Supplementary files

Publication details

The article was received on 15 Apr 2019, accepted on 02 Aug 2019 and first published on 02 Aug 2019


Article type: Paper
DOI: 10.1039/C9CE00567F
CrystEngComm, 2019, Advance Article

  •   Request permissions

    Improving solubility and storage stability of rifaximin via solid-state solvation with Transcutol®

    F. Grepioni, D. Braga, L. Chelazzi, O. Shemchuk, P. Maffei, A. Sforzini and G. C. Viscomi, CrystEngComm, 2019, Advance Article , DOI: 10.1039/C9CE00567F

Search articles by author

Spotlight

Advertisements